Sign in or create an account to add this stock to your watchlist.
About CareDx (NASDAQ:CDNA)
CareDx, Inc., a transplant diagnostics company, together with its subsidiaries, engages in the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients worldwide. It operates through two segments, Post-Transplant Diagnostics and Pre-Transplant Diagnostics. The Post-Transplant Diagnostics segment develops and provides a diagnostic surveillance testing solution for heart and kidney transplant recipients. It offers AlloMap, a heart transplant molecular test; and AlloSure, a donor-derived cell free DNA test initially used for kidney transplant patients. The Pre-Transplant Diagnostics segment develops, manufactures, markets, and sells products that increase the chance of successful transplants by facilitating a match between a donor and a recipient of stem cells and organs. It sells Olerup SSP, which is used to type human leukocyte antigen (HAL) alleles based on sequence-specific primer technology; Olerup QTYPE, a test kit for sequence based HLA typing; Olerup SBT, a test kit for sequence based HLA typing; and XM-ONE, a test that identifies a patient's antigens against HLA Class I or Class II, as well as antibodies against a donor's endothelium. This segment offers its products directly to customers, as well as through third-party distributors. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in Brisbane, California.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CDNA
CUSIPN/A
Phone415-287-2300
Debt
Debt-to-Equity Ratio0.29
Current Ratio2.43
Quick Ratio2.06
Price-To-Earnings
Trailing P/E Ratio-15.35
Forward P/E Ratio-24.12
P/E GrowthN/A
Sales & Book Value
Annual Sales$48.32 million
Price / Sales8.63
Cash FlowN/A
Price / CashN/A
Book Value$0.95 per share
Price / Book12.44
Profitability
EPS (Most Recent Fiscal Year)($0.77)
Net Income$-55,460,000.00
Net Margins-115.91%
Return on Equity-158.93%
Return on Assets-19.78%
Miscellaneous
Employees179
Outstanding Shares35,280,000
CareDx (NASDAQ:CDNA) Frequently Asked Questions
What is CareDx's stock symbol?
CareDx trades on the NASDAQ under the ticker symbol "CDNA."
How were CareDx's earnings last quarter?
CareDx Inc (NASDAQ:CDNA) released its earnings results on Thursday, May, 10th. The company reported ($0.14) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.13) by $0.01. The firm earned $14.05 million during the quarter, compared to analyst estimates of $13.91 million. CareDx had a negative net margin of 115.91% and a negative return on equity of 158.93%. View CareDx's Earnings History.
What price target have analysts set for CDNA?
4 brokers have issued 12 month target prices for CareDx's stock. Their predictions range from $6.50 to $14.00. On average, they expect CareDx's stock price to reach $9.3750 in the next year. View Analyst Ratings for CareDx.
Who are some of CareDx's key competitors?
Some companies that are related to CareDx include Genomic Health (GHDX), Natera (NTRA), RadNet (RDNT), Invitae (NVTA), Enzo Biochem (ENZ), Veracyte (VCYT), Miragen Therapeutics (MGEN), Celcuity (CELC), Psychemedics (PMD), Fulgent Genetics (FLGT), First Choice Healthcare Solutions (FCHS), Cancer Genetics (CGIX), Biocept (BIOC), OpGen (OPGN) and Cord Blood America (CBAI).
Who are CareDx's key executives?
CareDx's management team includes the folowing people:
- Dr. Peter Maag, Pres, CEO & Director (Age 51)
- Mr. Michael Bell, Chief Financial Officer (Age 49)
- Dr. James P. Yee, Chief Medical Officer (Age 69)
- Dr. Mitchell J. Nelles, Chief Operating Officer (Age 65)
- Dr. John J. Sninsky Ph.D., Chief Scientific Officer (Age 68)
Has CareDx been receiving favorable news coverage?
Media coverage about CDNA stock has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. CareDx earned a coverage optimism score of 0.04 on Accern's scale. They also assigned press coverage about the company an impact score of 46.55 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Who are CareDx's major shareholders?
CareDx's stock is owned by many different of retail and institutional investors. Top institutional investors include Gagnon Securities LLC (5.08%), MIDROC INVEST AB (4.50%), Next Century Growth Investors LLC (4.47%), Polar Asset Management Partners Inc. (2.44%), Park West Asset Management LLC (1.41%) and Millrace Asset Group Inc. (0.85%). Company insiders that own CareDx stock include James P Yee, Michael Brian Bell, Mitchell J Nelles, Neil Gagnon and Peter Maag. View Institutional Ownership Trends for CareDx.
Which major investors are selling CareDx stock?
CDNA stock was sold by a variety of institutional investors in the last quarter, including Park West Asset Management LLC, Thompson Davis & CO. Inc. and Gagnon Securities LLC. Company insiders that have sold CareDx company stock in the last year include James P Yee, Mitchell J Nelles and Peter Maag. View Insider Buying and Selling for CareDx.
Which major investors are buying CareDx stock?
CDNA stock was acquired by a variety of institutional investors in the last quarter, including Polar Asset Management Partners Inc., Next Century Growth Investors LLC, Millrace Asset Group Inc., Millennium Management LLC, Spark Investment Management LLC, Trexquant Investment LP, Tibra Equities Europe Ltd and Clear Harbor Asset Management LLC. Company insiders that have bought CareDx stock in the last two years include Michael Brian Bell, Neil Gagnon and Peter Maag. View Insider Buying and Selling for CareDx.
How do I buy shares of CareDx?
Shares of CDNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CareDx's stock price today?
One share of CDNA stock can currently be purchased for approximately $11.82.
How big of a company is CareDx?
CareDx has a market capitalization of $416.34 million and generates $48.32 million in revenue each year. The company earns $-55,460,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis. CareDx employs 179 workers across the globe.
How can I contact CareDx?
CareDx's mailing address is 3260 BAYSHORE BOULEVARD, BRISBANE CA, 94005. The company can be reached via phone at 415-287-2300 or via email at [email protected]
MarketBeat Community Rating for CareDx (CDNA)
MarketBeat's community ratings are surveys of what our community members think about CareDx and other stocks. Vote "Outperform" if you believe CDNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
CareDx (NASDAQ:CDNA) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for CareDx in the last 12 months. Their average twelve-month price target is $9.3750, suggesting that the stock has a possible downside of 20.69%. The high price target for CDNA is $14.00 and the low price target for CDNA is $6.50. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $9.3750 | $8.8750 | $8.8750 | $7.8333 |
| Price Target Upside: | 20.69% downside | 2.96% upside | 45.25% upside | 39.38% upside |
CareDx (NASDAQ:CDNA) Consensus Price Target History
CareDx (NASDAQ:CDNA) Analyst Ratings History
Show:
(Data available from 5/25/2016 forward)
CareDx (NASDAQ:CDNA) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
CareDx (NASDAQ CDNA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.40%
Institutional Ownership Percentage: 51.87%
CareDx (NASDAQ CDNA) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/26/2018 | Neil Gagnon | Major Shareholder | Buy | 10,136 | $9.42 | $95,481.12 | 928,768 |  |
| 3/27/2018 | Peter Maag | Insider | Sell | 15,000 | $7.87 | $118,050.00 | 272,037 | |
| 12/8/2017 | James P Yee | Insider | Sell | 29,197 | $7.00 | $204,379.00 | 74,795 | |
| 11/30/2017 | Mitchell J Nelles | COO | Sell | 10,948 | $7.17 | $78,497.16 | 84,225 | |
| 10/5/2017 | Neil Gagnon | Major Shareholder | Buy | 10,642 | $4.00 | $42,568.00 | | |
| 9/7/2017 | Neil Gagnon | Major Shareholder | Buy | 6,496 | $3.05 | $19,812.80 | 916,546 | |
| 8/28/2017 | Neil Gagnon | Major Shareholder | Buy | 21,448 | $2.77 | $59,410.96 | 903,731 | |
| 8/25/2017 | Neil Gagnon | Major Shareholder | Buy | 35,119 | $2.92 | $102,547.48 | 890,473 | |
| 8/15/2017 | Michael Brian Bell | CFO | Buy | 725 | $1.83 | $1,326.75 | 375 | |
| 8/15/2017 | Peter Maag | Insider | Buy | 600 | $1.82 | $1,092.00 | 107,350 | |
| 7/24/2017 | Neil Gagnon | Major Shareholder | Buy | 1,486 | $1.23 | $1,827.78 | 886,216 | |
| 6/29/2017 | Neil Gagnon | Major Shareholder | Buy | 1,808 | $1.11 | $2,006.88 | 886,216 | |
| 6/23/2017 | Neil Gagnon | Major Shareholder | Buy | 63,120 | $1.10 | $69,432.00 | 886,216 | |
| 5/24/2017 | Neil Gagnon | Major Shareholder | Buy | 7,439 | $1.00 | $7,439.00 | 879,914 | |
| 5/23/2017 | Neil Gagnon | Major Shareholder | Buy | 6,836 | $1.04 | $7,109.44 | 878,777 | |
| 4/28/2017 | Neil Gagnon | Major Shareholder | Buy | 15,116 | $0.89 | $13,453.24 | 873,928 | |
| 3/16/2017 | Neil Gagnon | Major Shareholder | Buy | 123,160 | $1.83 | $225,382.80 | 778,133 | |
| 9/22/2016 | Neil Gagnon | Major Shareholder | Buy | 178,686 | $4.00 | $714,744.00 | 613,473 | |
| 4/14/2016 | Neil Gagnon | Major Shareholder | Buy | 93,240 | $4.02 | $374,824.80 | 419,638 | |
| 10/21/2015 | Neil Gagnon | major shareholder | Buy | 1,431 | $4.99 | $7,140.69 | 1,243,852 | |
| 10/20/2015 | Neil Gagnon | Major Shareholder | Buy | 1,347 | $4.92 | $6,627.24 | 1,242,421 | |
| 9/29/2015 | Neil Gagnon | major shareholder | Buy | 6,332 | $6.10 | $38,625.20 | 1,240,886 | |
| 9/4/2015 | Neil Gagnon | Major Shareholder | Buy | 69,383 | $6.95 | $482,211.85 | | |
| 6/5/2015 | Neil Gagnon | Major Shareholder | Buy | 6,500 | $5.69 | $36,985.00 | | |
| 6/1/2015 | Peter Maag | CEO | Buy | 2,000 | $4.84 | $9,680.00 | | |
| 4/17/2015 | Neil Gagnon | Major Shareholder | Buy | 13,051 | $5.34 | $69,692.34 | | |
| 3/20/2015 | Neil Gagnon | Major Shareholder | Buy | 6,324 | $6.35 | $40,157.40 | | |
| 2/27/2015 | Neil Gagnon | Major Shareholder | Buy | 4,270 | $6.03 | $25,748.10 | | |
| 2/6/2015 | Neil Gagnon | Major Shareholder | Buy | 4,586 | $7.20 | $33,019.20 | | |
| 2/5/2015 | Neil Gagnon | Major Shareholder | Buy | 121,587 | $7.10 | $863,267.70 | | |
| 2/4/2015 | Neil Gagnon | Major Shareholder | Buy | 31,991 | $7.00 | $223,937.00 | | |
| 2/3/2015 | Neil Gagnon | Major Shareholder | Buy | 23,558 | $7.03 | $165,612.74 | | |
| 2/2/2015 | Neil Gagnon | Major Shareholder | Buy | 3,620 | $7.05 | $25,521.00 | | |
| 1/29/2015 | Neil Gagnon | Major Shareholder | Buy | 15,395 | $7.04 | $108,380.80 | | |
| 1/27/2015 | Neil Gagnon | Major Shareholder | Buy | 84,720 | $7.00 | $593,040.00 | | |
| 1/22/2015 | Neil Gagnon | Major Shareholder | Buy | 48,670 | $7.13 | $347,017.10 | | |
| 1/20/2015 | Neil Gagnon | Major Shareholder | Buy | 16,192 | $6.66 | $107,838.72 | | |
| 1/15/2015 | Neil Gagnon | Major Shareholder | Buy | 39,109 | $6.43 | $251,470.87 | | |
| 1/14/2015 | Neil Gagnon | Major Shareholder | Buy | 122,319 | $7.07 | $864,795.33 | | |
| 7/22/2014 | Ken Ludlum | CFO | Buy | 7,000 | $10.00 | $70,000.00 | | |
| 7/22/2014 | Michael Goldberg | Director | Buy | 25,000 | $10.00 | $250,000.00 | | |
| 7/22/2014 | Perkins Caufield & Bye Kleiner | Major Shareholder | Buy | 52,770 | $10.00 | $527,700.00 | | |
(Data available from 1/1/2013 forward)
CareDx (NASDAQ CDNA) News Headlines
| Source: |
|
CareDx (NASDAQ:CDNA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
CareDx (NASDAQ:CDNA) Income Statement, Balance Sheet and Cash Flow Statement
CareDx (NASDAQ CDNA) Stock Chart for Friday, May, 25, 2018
Loading chart…
